Expanded Formulation and Analytical Development Laboratories open

Tuesday 29th April 2008, 9 AM

On 29th April 2008, just 36 months after moving into new premises in Livingston, Encap Drug Delivery, in partnership with Thermal Transfer, has completed the first phase of its next extension by opening a major new 200 square metre laboratory suite that will be dedicated to Formulation, Production and Analytical Development.  The second phase is a further 450 square metre manufacturing facility and is due for completion in July 2008. This new facility will include two separate suites for large-scale pharmaceutical processing. One suite will be dedicated to the manufacture of products requiring special handling (e.g high potency and anti-cancer products).

Completion of both phases will represent a significant new stage in the company’s growth and a ‘first’ in Scottish full-scale manufacturing for such products. The expansion will eventually bring the number of company employees to 50.

Encap was established in Livingston, Scotland in 1989 and has seen a steady growth in its liquid fill encapsulation technology. The company operates to cGMP, and holds MHRA manufacturing licences for both Investigational Medicinal Procedures (IMP’s) and marketed products, and is able to meet the stringent quality requirements set by the world’s most demanding regulatory bodies. The company has a wide range of international Pharmaceutical and Biotechnology clients and currently manufactures EU licensed pharmaceutical products for eight companies.

Liquid-fill based formulation is one of the fastest growing sectors of the drug delivery market, increasing at a rate of 30% per annum. This is due to the number of highly potent chemical and biological-based drugs moving through development pipelines. This investment is part of a £3 M capital outlay by the company to further grow its international presence in drug delivery in an area that primarily focuses on liquid and semi-solid encapsulation using two-piece hard-shell capsules.

Encap Drug Delivery Strengthens Capability in High-Potency and Cytotoxic Encapsulation

Friday 10th August 2007, 9 AM

Encap, the international drug delivery solutions provider, today announced that it has signed an agreement with Thermal Transfer Limited (TTL) to build a £3 million state-of-the-art pharmaceutical development and manufacturing facility in Livingston, Scotland. Construction has already started on the new facility, which will be approved and operational by June 2008.

Under this agreement, TTL will deliver a high-specification, modern facility that will expand Encap’s current R&D and production plant to over 40,000 ft2. The new facility also includes dedicated, high-containment suites that strengthen Encap’s integrated capability in formulation development, clinical and commercial manufacture of high-potency and cytotoxic compounds.

The expansion has been driven by escalating demand from worldwide Customers for the Company’s liquid-fill two-piece capsule technologies, facilities and know-how. Encap’s specialist encapsulation technologies are ideally suited for new product development and life-cycle extension. Liquid-fill encapsulation is one of the fastest growing sectors of the drug delivery market, increasing at a rate of 10-30% per annum. The technology offers many advantages including enhanced bioavailability, rapid formulation development, contained manufacturing and safe handling.

Dr. Stephen Brown joins as R&D Director
Tuesday 2nd January 2007, 9 AM

Encap, the international drug delivery solutions provider, has strengthened its Board of Directors and appointed Dr Stephen Brown as R&D Director with immediate effect. Dr Brown brings with him 20 years pharmaceutical development experience coupled with significant leadership expertise. Dr Brown has proven abilities in product development and commercialisation, and his career to date has included senior management positions in UCB Celltech, Chiroscience and Sanofi.

Reflecting Encap’s commitment to broaden its product and service offerings, Dr Brown’s role includes building strategic partnerships with technology innovators to source novel, differentiated delivery technologies for in-licensing, acquisition or joint venture opportunities.

Dr Brown commented, “I am looking forward to fresh, new challenges at Encap. The Company has a well-established reputation as a world leader in liquid-filled two-piece capsules. We aim to provide solutions to the drug delivery issues faced by our customers today and in the future. I am confident in adding-value to Encap’s existing portfolio of proprietary technologies and maximising our product and service offerings to customers.”

Encap Drug Delivery Announces Plans for Expansion

Tuesday 10th October 2006, 9 AM

Encap, the international drug delivery solutions provider, announced today that it has signed a Head of Terms with Kenmore Capital Oakbank Ltd and secured a long-term lease for a new 14,000 sq. ft facility at Oakbank Park Way, Livingston, Scotland. The site is adjacent to Encap’s current R&D and production plant and will contain additional microbiology and developmental laboratories, state-of-the-art capsule filling suites and dedicated cytotoxic units.

Notes to Editors

Encap is an international drug delivery solutions provider with fully integrated capabilities in oral drug delivery, contract development and commercial manufacture. Encap is a world leader in liquid-filled two-piece capsules. Established in 1989, the Company is headquartered near Edinburgh, Scotland and offers capsule development and commercial manufacture for NCEs and marketed small molecules, biologicals and nutraceuticals on a fee-for-service basis. The Company’s current commercial production capacity exceeds 300 million capsules per annum.

Encap also partners companies throughout Europe, North America and Asia to improve the oral delivery of developmental candidates and extend the lifecycles of existing products. The Company’s proprietary technologies include liquid-fill, DuoCaps, Abusolve ™ and LayerCap ™ .

For more information, please contact

t : +44 (0) 1506 448080

f : +44 (0) 1506 448081
e: enquiry@encapdrugdelivery.comnquiry@encapdrugdelivery.com

nquiry@encapdrugdelivery.com